The company has also opened an additional study and recruiting patients at the Stanford University Medical Center in Palo Alto, CA.
The study aims to investigate safety and efficacy parameters, including improvements in motor function and cognitive status.
SB623 has been shown to improve neurological behavior in preclinical models of stroke
SanBio Co-CEO Keita Mori said with two trial sites now open, their goal is to explore the potential of SB623 as a potential treatment for stroke disability as rapidly as possible.
"SB623 represents a significant step forward in the development of regenerative therapies," Mori said.